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Abstract Insulin-like growth factors (IGFs) are a group of
proteins that promote cell growth and differentiation. Long-[Arg-
3]-IGF-I (Francis et al. (1992) J. Mol. Endocrinol. 8, 213^223),
a potent analogue of IGF-I, which has a Glu-3 to Arg-3
substitution and a hydrophobic, thirteen amino acid N-terminal
extension, has been studied by 1H,15N NMR spectroscopy. All
the backbone 1H and 15N assignments and most of the 1H
sidechain assignments have been completed. The secondary
structure elements were identified by determining the sequential
and medium range NOEs from sensitivity-enhanced 15N-
NOESY-HSQC and sensitivity-enhanced 15N-HSQC-
NOESY-HSQC spectra. The IGF-I domain of Long-[Arg-3]-
IGF-I was found to have an almost identical structure to IGF-I.
The N-terminal seven amino acid residues of the extension have
very few medium range or long range NOEs but the next five
amino acids form a turn-like structure that is spatially close to
the beginning of helix 1 in the IGF-I domain. Hydrogen-
deuterium exchange experiments show that all the slowly
exchanging backbone amide protons in the IGF-I domain are
either in the helical or the extended structural elements. Many of
the amide protons in the N-terminal extension are also protected
from the solvent although the residues in this part of the
extension do not have any identifiable secondary structure. The
results are interpreted in terms of the increased biological
potency of Long-[Arg-3]-IGF-I and the decreased binding to
insulin-like growth factor binding proteins.
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1. Introduction
Insulin-like growth factors (IGFs) are single chain polypep-
tides which exhibit a high degree of sequence similarity with
insulin [1^3]. The two forms, IGF-I and IGF-II, are found in
plasma and most biological £uids. IGF-I is primarily known
as a mitogenic agent which is involved in the regulation of cell
growth and di¡erentiation [4].
IGFs exert their biological e¡ects by binding to target cell
surface receptors and activating intracellular tyrosine kinases
[5]. IGFs are often bound to insulin-like growth factor bind-
ing proteins (IGFBPs) in vivo which modulate the transport
and delivery of IGFs to cell receptors [6]. The various classes
of IGFBPs exhibit considerable sequence similarity among
themselves. The nature of the interactions between the
IGFBPs and IGFs is not known although residues on the
ligand critical for binding have been identi¢ed [5,7^9].
IGF-I consists of 70 amino acids and has four well de¢ned
domains; B, C, A and D beginning from the N-terminus [4].
Fifty percent of the residues from the A and B domains are
identical to the A and B domains of insulin. The C domain of
IGF-I is comparable to the C domain of pro-insulin, but has
no sequence homology with the latter. The D domain is a C-
terminal extension of eight residues which has no correspond-
ing segment in insulin [10]. The secondary structure [11,12]
and the three-dimensional structure [12,13] of IGF-I have re-
cently been determined by 1H NMR spectroscopy and com-
puter-based methods. The protein contains three K-helices, the
¢rst in the B domain (Ala-8 to Cys-18), and the other two in
the A domain (Ile-43 to Phe-49 and Leu-54 to Cys-61). The
latter two run antiparallel to each other because of a disul-
phide cross-link between Cys-47 and Cys-52. The remaining
two disulphide cross-links are between Cys-18 and Cys-61,
and Cys-6 and Cys-48. Following K-helix 1, a L-turn leads
into a poorly de¢ned C domain. The D domain is also poorly
de¢ned.
Recombinant fusion protein analogues of IGF-I, in which
the N-terminal region has been modi¢ed, show increased bio-
logical potency [7] and have attracted great commercial inter-
est. For example, Long-[Arg-3]-IGF-I, in which Glu-3 in hu-
man IGF-I is replaced by Arg-3 and the N-terminus has a 13
amino acid extension consisting of the ¢rst 11 amino acids of
methionyl porcine growth hormone followed by the dipeptide
Val-Asn, is one of the most potent of these analogues [8,9]. It
has been postulated that the increased potency of Long-
[Arg-3]-IGF-I is due to reduced binding to the IGFBPs rather
than increased a⁄nity for the cell receptors [9]. The poor
binding a⁄nity for IGFBPs implies more free growth factor
is available for interaction with the cellular receptors [9].
It is unclear whether this increased potency of Long-
[Arg-3]-IGF-I is due to the N-terminal region having a direct
e¡ect on binding to IGFBPs or the N-terminal extension dis-
rupting the secondary structure of regions of IGF-I involved
in IGFBP binding. Here, we report the resonance assignment,
secondary structure determination and global fold of Long-
[Arg-3]-IGF-I, with particular focus on the N-terminal exten-
sion. This work serves as a basis for a future structural anal-
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ysis of the biological activity of Long-[Arg-3]-IGF-I and the
design of further IGF-I analogues.
2. Material and methods
2.1. Long-[Arg-3]-IGF-I expression and puri¢cation
E. coli strain JM101 was transformed with the p[Met1]-pGH(11)-
Val-Asn-IGF-I expression vector and maintained on minimal medium
as described by King et al. [8]. The Long-[Arg-3]-IGF-I expression
strain was grown in a 2 l fermenter by Bresatec Ltd. (Adelaide, Aus-
tralia), employing a minimal medium containing 3.22 g/l 15NH4Cl as
the sole nitrogen source [8]. Growth was controlled at 37‡C, 55% pO2
and pH 7.0 maintained with NaOH feeding. Cells were induced at an
optical density (OD 600) of 10 with 250 Wmol/l isopropyl-L-D-thiolga-
lactoside and grown for a further 6 h. Homogenisation and inclusion
body isolation were performed as described by King et al. [8]. 15N-
labelled Long-[Arg-3]-IGF-I was refolded and puri¢ed as described by
Francis et al. [9]. Amino acid analysis of the ¢rst 18 N-terminal
residues was used to con¢rm identity and indicated s 96% purity.
A single species of 9222 þ 2 Da was detected by electrospray mass
spectrometry, indicative of 100% incorporation of 15N (theoretical
mass 9223).
2.2. NMR spectroscopy
NMR measurements were performed at 30‡C on both 15N-labelled
and unlabelled protein. The 15N-Long-[Arg-3]-IGF-I was dissolved to
a concentration of 1.0 mM in 90% H2O/10% D2O, at pH 4.1. The
unlabelled Long-[Arg-3]-IGF-I was dissolved to a concentration of 1.3
mM in 100% D2O at pH 4.1. Initial 2D and 3D NMR experiments
were carried out on a Varian VXR-500S NMR spectrometer. Subse-
quent NMR experiments were performed on Varian INOVA-500 and
Varian INOVA-600 spectrometers. The following experiments were
collected on the 15N-labelled protein in 90% H2O/10% D2O bu¡er:
sensitivity-enhanced 15N-HSQC [14], 15N-HMQC-J [15], 2D 15N-
HSQC-TOCSY [16] with a mixing time of 70 ms, 3D sensitivity-en-
hanced 15N-TOCSY-HSQC [16] with a mixing time of 70 ms, 3D
sensitivity-enhanced 15N-NOESY-HSQC [16] with mixing times of
80 ms and 140 ms, 3D sensitivity-enhanced 15N-HSQC-NOESY-
HSQC [16] with a mixing time of 140 ms and a 3D sensitivity-en-
hanced 15N-HSQC-TOCSY-NOESY-HSQC [16] with a NOESY mix-
ing time of 100 ms and a TOCSY mixing time of 35 ms. All the above
experiments employed pulsed ¢eld gradients. A 2D NOESY spectrum
with a mixing time of 150 ms and a 2D TOCSY spectrum with a
mixing time of 80 ms and a 3D TOCSY-NOESY with a NOESY
mixing time of 150 ms and a TOCSY mixing time of 50 ms [17]
were collected on an unlabelled protein sample at a concentration
of 1.3 mM in identical solution conditions except 100% D2O was
used.
Multidimensional Fourier transformation, employing linear predic-
tion, was performed with Varian VNMR version 5.2 software (Varian
Associates, Palo Alto, CA). After transformation, the processed data
from all experiments except the 15N-HMQC-J dataset were converted
into XEASY format [18] for spectral analysis. All peak picking, spec-
tral analysis and semiautomated resonance assignments were per-
formed with the XEASY software package [18]. 3JHNK coupling con-
stants were estimated from the splittings in the 15N-HMQC-J dataset
by J deconvolution [19] using an ‘in house’ software package (C.J.
Blake and M.A. Keniry, unpublished results).
Hydrogen exchange was performed by lyophilising the 15N-labelled
Long-[Arg-3]-IGF-I solution and reconstituting the sample in 99.9%
D2O. A series of 15N,1H-HSQC spectra was collected at 20‡C at
intervals of 1 h, 4 h and 24 h. The elapsed time between reconstitution
and the start of the ¢rst HSQC experiment was 15 min and each
HSQC spectrum was acquired in 30 min.
3. Results and discussion
3.1. Resonance assignment
Spin system identi¢cation was achieved by analysis of 2D
HSQC-TOCSY and 3D TOCSY-HSQC spectra using well
established techniques. Sequential resonance assignment was
performed following procedures pioneered by Wuºthrich and
coworkers [20] and utilised 3D NOESY-HSQC and 3D
HSQC-NOESY-HSQC spectra. The proline spin systems
were assigned by analysis of 2D NOESY and 3D TOCSY-
NOESY spectra. The 1H-15N sensitivity-enhanced HSQC
spectrum of Long-[Arg-3]-IGF-I is presented in Fig. 1. The
1H and 15N resonance assignments have been submitted to the
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Fig. 1. The 1H-15N sensitivity enhanced HSQC spectrum of Long-[Arg-3]-IGF-I. Assignments for the backbone amides are labelled.
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BioMagResBank (accession number: pending). The amino
acid sequence of Long-[Arg-3]-IGF-I is numbered from the
N-terminus of the parent human IGF-I. The N-terminus of
Long-[Arg-3]-IGF-I is designated as Met-13, the N-terminal
extension continues to Asn-1 where the IGF-I domain starts
at Gly-1 and proceeds to the C-terminal Ala-70. As well as the
76 major cross-peaks in Fig. 1, there is a subset of low inten-
sity cross-peaks that probably arise from a minor species in
solution. None of these low intensity cross-peaks gives rise to
observable NOEs in the NOESY-HSQC spectrum. Only one
resonance, assigned to Gly-42, is split into two distinct peaks
of equal intensity. Inspection of the NOESY-HSQC spectrum
revealed an identical NOE pattern for each diagonal peak.
Gly-42 is close to Pro-39 and the doubling of its cross-peak
may be a result of cis-trans isomerism at this proline.
The secondary structure elements in Long-[Arg-3]-IGF-I
were identi¢ed from the relative intensities of sequential
KN(i,i+1) and NN(i,i+1) NOEs, medium range KN(i,i+2),
KN(i,i+3) and KN(i,i+4) NOEs, and J coupling information
and were con¢rmed by analysis of the deviation of the chem-
ical shifts of the K-CH protons from their random coil values
[21]. A diagrammatic summary of the results of this analysis is
presented in Fig. 2.
It is apparent from an examination of the pattern of NOEs
of Long-[Arg-3]-IGF-I with the NOEs of the parent protein
that the Met-13 to Asn-1 N-terminal extension has very little
e¡ect on the secondary structure of the IGF-I domain. Thus,
medium to strong sequential NN(i,i+1) NOEs are observed
for the segments Ala-8 to Phe-23, Ile-43 to Arg-50 and Leu-
54 to Ala-62 and medium range KN(i,i+3) NOEs are detected
for the segments Ala-8 to Cys-18, Ile-43 to Arg-50 and Leu-54
to Met-59. Furthermore, KN(i,i+4) NOEs are also observed in
these regions (Fig. 2). Such NOE patterns are typically found
in the helical regions of proteins and hence this places the
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Fig. 2. A summary of the NMR data de¢ning the secondary structure of Long-[Arg-3]-IGF-I at 30‡C and pH 4.1. The primary sequence is dis-
played at the top. Sequential NOE connectivities, dNN, dKN and dLN, are indicated by bars linking the residues concerned and are classi¢ed as
strong, medium or weak according to the thickness of the bar. Medium range NOE connectivities, dKN(i,i+2), dKN(i,i+3) and dKN(i,i+4), are
linked by lines. The chemical shift index (de¢ned as the deviation of the chemical shift value of the K proton from its random coil value by
greater than 0.1 ppm) is classi¢ed as positive or negative by vertical lines above and below a baseline respectively. 3JHNK values greater than
7.5 Hz are indicated by an upright arrow, 3JHNK values less than 6 Hz are indicated by an inverted arrow. Un¢lled circles indicate amide pro-
ton resonances that are observable 1 h after exchange of the solvent from H2O to D2O. Filled circles indicate amide proton resonances that
are observed 24 h after solvent exchange.
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three helices in the IGF-I domain in approximately the same
location as in the parent IGF-I protein. Strong KN(i,i+1)
NOEs are observed in the segments Thr-4 to Leu-5, Cys-6
to Ala-8, Gly-19 to Tyr-24 and Thr-29 to Ala-39 suggesting
that these regions are in extended conformations as in IGF-I
[11^13]. Medium range KN(i,i+2) NOEs are detected between
Gly-19 and Arg-21 and between Asp-20 and Gly-22 indicating
that the L-turn observed in this region of IGF-I [11] is pre-
served in the IGF-I domain of Long-[Arg-3]-IGF-I. The mag-
nitude of some NOEs was uncertain in previous homonuclear
studies of IGF-I [11^13] because of overlap in some regions.
In this work, these regions are better de¢ned because the pulse
sequences employed pulsed ¢eld gradients for coherence selec-
tion and the resonances were dispersed along the nitrogen
dimension of the F2 domain [16]. Rapidly exchanging protons
are more readily observed because of these recent technolog-
ical developments. The Val-11 cross-peak in the HSQC spec-
trum is broad and shifted up¢eld as in the native IGF-I [11]
suggesting a remarkably similar structural element that is re-
tained at the start of helix 1 near the N-terminal extension.
Many of the long range NOEs that are observed in native
IGF-I are also observed in the IGF-I domain of Long-
[Arg-3]-IGF-I (Fig. 3) suggesting that the addition of the N-
terminal extension has little or no e¡ect on the three-dimen-
sional fold of the parent IGF-I domain.
The N-terminal segment of the extension, from Met-13 to
Ser-5 has little or no recognisable structure, as judged by the
paucity of non-sequential NOEs. Based on the pattern of
NOEs, the segment from Leu-4 to Gly-1 has features reminis-
cent of a turn-type structure. Thus, medium range NOEs are
observed between the amide protons of Leu-4 and Val-2 and
several ‘reversed’ sequential NOEs are observed between the
amide proton of Phe-3 and the K, L and Q protons of Val-2.
On the basis of this NOE pattern it is not possible to assign
this turn to any of the standard types. Interestingly, long
range NOEs are observed between Phe-3 and Gly-7 and be-
tween Val-2 and Cys-6 which place the segment Leu-4 to Gly-
1 over the N-terminal end of the IGF-I domain and near the
start of helix 1.
Hydrogen-deuterium exchange is frequently used to locate
amide protons that are hydrogen-bonded or inaccessible to
the solvent. The hydrogen exchange patterns in the IGF-I
domain are in agreement with the secondary structure ele-
ments and are also consistent with previous homonuclear
studies of wild-type IGF-I [11,13]. Helix 1 displays slow amide
exchange along the whole length of the helix whereas only
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Fig. 3. Strips from the 3D sensitivity enhanced 15N-NOESY-HSQC spectrum of Long-[Arg-3]-IGF-I displaying the sequential and long range
contacts observed for the region from S-5 to L5.
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some of the amide protons within the other two shorter heli-
ces are protected from the solvent. Residues within the short
stretch of extended structure (Gly-30 to Ala-39) are also pro-
tected from solvent. This Gly-30-Ala-39 region of native IGF-
I was poorly de¢ned in the homonuclear studies and did not
display any solvent protection [11,13], thus it is not clear
whether this is a real di¡erence between Long-[Arg-3]-IGF-I
and IGF-I or a limitation of the homonuclear studies. IGF-II
has a smaller stretch of residues in an extended conformation
between helix 1 and helix 2 that are also protected from sol-
vent exchange but, compared to Long-[Arg-3]-IGF-I, this re-
gion is o¡set ¢ve residues toward the N-terminus at Gly-25 to
Phe-28 [22]. A long stretch of residues in the N-terminal ex-
tension (Met-13 to Leu-4) is also protected from solvent. This
is a surprising result since most protected amide protons are
involved in hydrogen bonds [23] but no well de¢ned secondary
structure exists in this part of the N-terminal extension. The
pattern of solvent protection may re£ect the hydrophobic na-
ture of the extension which arranges the residues in such a
way as to exclude solvent but these structures must be tran-
sitory since this region is also poorly de¢ned in preliminary
distance geometry structural studies.
Previous studies have shown that Glu-3 in the native IGF-I
is an important residue in mediating the binding of IGF-I to
the IGFBPs [5,7,8]. Thus, removal of the ¢rst three N-termi-
nal residues or replacement of Glu-3 with a hydrophobic or a
positively charged residue substantially reduces the binding of
IGF-I to the IGFBPs [9]. Adding a 13 amino acid hydropho-
bic N-terminal extension to IGF-I (Long-IGF-I) further re-
duces the binding to the IGFBPs. Substituting Arg-3 for Glu-
3 in Long-IGF-I to form Long-[Arg-3]-IGF-I substantially
decreases the binding to the IGFBPs even further. In this
variant, the presence of the hydrophobic extension and re-
placement of Glu-3 with Arg-3 also reduces, to a lesser extent,
the binding of the Long-[Arg-3]-IGF-I analogue to the IGF-I
receptor compared to native IGF-I but still increases its bio-
logical activity ¢ve- to ten-fold over the latter [9]. This work
has shown that the reduced binding of Long-[Arg-3]-IGF-I to
the IGFBPs can be explained in terms of the replacement of
Glu-3 by Arg-3 and also by masking the N-terminus of IGF-I
from the IGFBPs by the hydrophobic extension. The latter
may explain the decreased binding to the IGFBPs and resul-
tant increased biological potency of Long-[Arg-3]-IGF-I com-
pared to native IGF-I. Association of Long-[Arg-3]-IGF-I
with the IGFBPs is most likely prevented by steric hindrance
caused by the partially structured N-terminal extension im-
peding access to Gly-1 and Pro-2 combined with the e¡ect
of the charge reversal caused by substituting Arg-3 for Glu-
3. A preliminary structure of Long-[Arg-3]-IGF-I displaying
the proximity of the N-terminal extension (shaded in black) to
Gly-1, Pro-2 and Arg-3 and the start of helix 1 is shown in
Fig. 4.
An explanation for the reduced binding of Long-[Arg-3]-
IGF-I to the IGF-I receptor is less obvious, since the IGF-I
receptor recognises mainly aromatic residues at positions 24
and 31 in native IGF-I and to a lesser extent C and A domain
residues [24]. Although the start of helix 1 at Ala-8 is a long
way from these two aromatic residues in terms of the primary
structure, Ala-8 is su⁄ciently close in space for a point muta-
tion at this residue to reduce the binding of IGF-I to the IGF-
I receptor [25]. The observation of long range NOEs between
Phe-3 and Val-2 in the extension with Gly-7 and Cys-6 re-
spectively, places the extension su⁄ciently close to the start of
helix 1 to interfere with the binding of Long-[Arg-3]-IGF-I to
the IGF-I receptor. It is also possible that there may be non-
speci¢c binding of the mobile N-terminal part of the hydro-
phobic extension of Long-[Arg-3]-IGF-I to the IGF-I receptor
thereby preventing the speci¢c binding that is required for the
receptor to mediate its biological action.
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